Medicamen Biotech Ltd (BSE: 531146) is a New Delhi, Delhi-based company in the Pharmaceuticals industry. With a market capitalisation of ₹389 Cr, it ranks #2,142 by market cap among the 6,137 Indian listed companies on FinBizNet, and #30 of 63 in Pharmaceuticals. At ₹253.35 (as of 25 Oct 2026), the share price is 43.4% below its 52-week high of ₹447.65 and 19.3% above its 52-week low of ₹212.40. The share price is down 20.9% over one year and up 4.8% over three months.
| Current Price | ₹253.35 |
|---|---|
| Market Cap | ₹389 Cr |
| BSE Code | 531146 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 38.7 |
| Return on Equity | 4.01% |
| Return on Assets | 2.31% |
| 52-Week Range | ₹212.40 – ₹447.65 |
| 1-Year Price Change | -20.9% |
| 3-Month Price Change | +4.8% |
| Beta (1Y) | 0.71 |
| Dividend Yield | 0.36% |
| Headquarters | New Delhi, Delhi |
| Website | www.medicamen.com |
| Revenue | ₹48 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| Net Margin | 3.9% |
| EPS (Basic) | ₹1.36 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarials, vitamins, antibiotics, and supplements, other generics, and pain management. The company was incorporated in 1993 and is based in New Delhi, India.
1. Pharmaceuticals Formulations-This segment engages in the development and manufacture of pharmaceutical products.
1. Pharmaceuticals Formulations-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Medicamen Biotech Ltd | ₹389 Cr | 38.7 | 4.01% | ₹48 Cr | -20.9% |
Listed by market capitalisation. Ratios are shown for context only.
Medicamen Biotech Ltd is trading at ₹253.35, with a market capitalisation of ₹389 Cr.
Medicamen Biotech Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Medicamen Biotech Ltd has a P/E of 38.7 and a return on equity of 4.01%.
Medicamen Biotech Ltd is listed on the BSE under the scrip code 531146.
Medicamen Biotech Ltd's share price is down 20.9% over one year and up 4.8% over three months. Its 52-week range is ₹212.40 to ₹447.65.
In Q1 FY27, Medicamen Biotech Ltd reported revenue of ₹48 Cr and net profit of ₹2 Cr, with basic EPS of ₹1.36 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.